FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667084> ?p ?o ?g. }

• W4385667084 endingPage "e2371389" @default.
• W4385667084 startingPage "e2371389" @default.
• W4385667084 abstract "Background: Next Generation Sequencing (NGS) is a rapidly evolving technique that simultaneously identifies several somatic mutations and quantifies allele burden. Therefore, it could be suitable for MRD monitoring in MDS patients. Traditionally its main limitations have been high single base error rates, which limited sensibility to 0.1-1%. However, sensitivities up to 10-4 can be achieved by applying novel ultrasensitive personalized sequencing techniques. Aims: This study explores the applicability of NGS for MRD and chimerism monitoring in MDS patients in the post-transplant setting. Methods: Twenty patients underwent ASCT between 2017 and 2022 in our center. Seven patients were excluded due to procedure-related mortality or relapse before 100-day follow-up, and six were excluded due to unavailable samples. We finally sequenced twenty-five samples from seven patients. Donor and receptor genomic DNA was sequenced with an in-house PhasedSNP panel that covers 58 regions with paired polymorphisms in less than 15bp. Receptor DNA was also sequenced with a 42-gene NGS panel (Ion TorrentTM) to identify somatic mutations used in follow-up samples to quantify MRD as previously described (Onecha E. Haematologica 2019). Briefly, an amplicon-multiplexed mini-panel was defined for every patient to detect the selected MRD biomarkers and donor/receptor phased SNPs identified at diagnosis. The mini-panel included molecular-tagged primer pairs to amplify every selected marker in three biological replicates, finally combined in the same library. Final libraries were sequenced on the Ion S5 System platform with an estimated depth of 500,000× per amplicon (median 151,242 reads). A median of 648 ng (range 180 - 662.4 ng) from bone marrow follow-up samples was sequenced. Results: The mean age at diagnosis was 53.6 years (SD 8.6). Risk at diagnosis according to IPSS-R score was intermediate in one patient (14.2%), high in four (57.1%) and very high in two (28.5%). The NGS-based MRD testing demonstrated high applicability: 6/7 patients (85.7%) had at least one somatic mutation suitable for MRD monitoring and 5/7 patients had more than one mutation. Phased SNPs chimerism was applicable in all the subjects. In most patients, we detected low levels of both MRD and receptor chimerism in post-transplant samples, usually below 1%. For all post-ASCT samples, MRD detection using flow cytometry was negative. The correlation between phased SNPs chimerism and MRD detection, both NGS-based, was very high (R=0.922; p=2.85 · 10-9) (Figure 1). However, qPCR-based chimerism and NGS-based phased SNPs chimerism showed some differences: in five cases, NGS-chimerism levels below 0.5% were undetectable by qPCR. NGS detected all cases with positive qPCR chimerism, but in six samples, chimerism quantification was slightly different between the two techniques. Summary/Conclusion: NGS-based MRD detection in MDS is feasible and has high applicability and sensitivity up to 10-4, with several advantages compared to traditional methods. Further research is warranted to study the relationship between MRD detection and clinical outcomes.Keywords: Myelodysplastic syndrome, Measurable residual disease, Chimerism quantification" @default.
• W4385667084 created "2023-08-09" @default.
• W4385667084 creator A5024436174 @default.
• W4385667084 creator A5026001642 @default.
• W4385667084 creator A5033061740 @default.
• W4385667084 creator A5034182883 @default.
• W4385667084 creator A5041532884 @default.
• W4385667084 creator A5041947496 @default.
• W4385667084 creator A5043547480 @default.
• W4385667084 creator A5045738997 @default.
• W4385667084 creator A5046714248 @default.
• W4385667084 creator A5055020157 @default.
• W4385667084 creator A5081131857 @default.
• W4385667084 date "2023-08-01" @default.
• W4385667084 modified "2023-10-18" @default.
• W4385667084 title "P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)" @default.
• W4385667084 doi "https://doi.org/10.1097/01.hs9.0000969712.23713.89" @default.
• W4385667084 hasPublicationYear "2023" @default.
• W4385667084 type Work @default.
• W4385667084 citedByCount "0" @default.
• W4385667084 crossrefType "journal-article" @default.
• W4385667084 hasAuthorship W4385667084A5024436174 @default.
• W4385667084 hasAuthorship W4385667084A5026001642 @default.
• W4385667084 hasAuthorship W4385667084A5033061740 @default.
• W4385667084 hasAuthorship W4385667084A5034182883 @default.
• W4385667084 hasAuthorship W4385667084A5041532884 @default.
• W4385667084 hasAuthorship W4385667084A5041947496 @default.
• W4385667084 hasAuthorship W4385667084A5043547480 @default.
• W4385667084 hasAuthorship W4385667084A5045738997 @default.
• W4385667084 hasAuthorship W4385667084A5046714248 @default.
• W4385667084 hasAuthorship W4385667084A5055020157 @default.
• W4385667084 hasAuthorship W4385667084A5081131857 @default.
• W4385667084 hasBestOaLocation W43856670841 @default.
• W4385667084 hasConcept C104317684 @default.
• W4385667084 hasConcept C126322002 @default.
• W4385667084 hasConcept C143998085 @default.
• W4385667084 hasConcept C164928082 @default.
• W4385667084 hasConcept C2778461978 @default.
• W4385667084 hasConcept C2779823535 @default.
• W4385667084 hasConcept C49105822 @default.
• W4385667084 hasConcept C51679486 @default.
• W4385667084 hasConcept C54355233 @default.
• W4385667084 hasConcept C70721500 @default.
• W4385667084 hasConcept C71924100 @default.
• W4385667084 hasConcept C8185291 @default.
• W4385667084 hasConcept C86803240 @default.
• W4385667084 hasConceptScore W4385667084C104317684 @default.
• W4385667084 hasConceptScore W4385667084C126322002 @default.
• W4385667084 hasConceptScore W4385667084C143998085 @default.
• W4385667084 hasConceptScore W4385667084C164928082 @default.
• W4385667084 hasConceptScore W4385667084C2778461978 @default.
• W4385667084 hasConceptScore W4385667084C2779823535 @default.
• W4385667084 hasConceptScore W4385667084C49105822 @default.
• W4385667084 hasConceptScore W4385667084C51679486 @default.
• W4385667084 hasConceptScore W4385667084C54355233 @default.
• W4385667084 hasConceptScore W4385667084C70721500 @default.
• W4385667084 hasConceptScore W4385667084C71924100 @default.
• W4385667084 hasConceptScore W4385667084C8185291 @default.
• W4385667084 hasConceptScore W4385667084C86803240 @default.
• W4385667084 hasIssue "S3" @default.
• W4385667084 hasLocation W43856670841 @default.
• W4385667084 hasLocation W43856670842 @default.
• W4385667084 hasOpenAccess W4385667084 @default.
• W4385667084 hasPrimaryLocation W43856670841 @default.
• W4385667084 hasRelatedWork W1983594995 @default.
• W4385667084 hasRelatedWork W2016680388 @default.
• W4385667084 hasRelatedWork W2315730663 @default.
• W4385667084 hasRelatedWork W2414074348 @default.
• W4385667084 hasRelatedWork W2556011949 @default.
• W4385667084 hasRelatedWork W2558227436 @default.
• W4385667084 hasRelatedWork W2765656200 @default.
• W4385667084 hasRelatedWork W2799005577 @default.
• W4385667084 hasRelatedWork W2909576866 @default.
• W4385667084 hasRelatedWork W2409976444 @default.
• W4385667084 hasVolume "7" @default.
• W4385667084 isParatext "false" @default.
• W4385667084 isRetracted "false" @default.
• W4385667084 workType "article" @default.